Thiogenesis Therapeutics, Corp. (TSXV:TTI)

Thiogenesis Therapeutics Income Statement

Financials in millions CAD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Selling, General & Admin	1.64	1.63	1.36	1.04	0.93	0.31
Research & Development	5.23	5.77	2.22	4.16	1.08	1.37
Operating Expenses	6.88	7.4	3.58	5.21	2.01	1.67
Operating Income	-6.88	-7.4	-3.58	-5.21	-2.01	-1.67
Interest Expense	-	-	-	-	-0	-0
Interest & Investment Income	0.02	0.05	0.2	0.17	0.01	-
Currency Exchange Gain (Loss)	-0.07	-0.08	0.23	-0.03	-	-
Other Non Operating Income (Expenses)	-	-	-	-	0.1	0.46
EBT Excluding Unusual Items	-6.93	-7.43	-3.15	-5.06	-1.91	-1.22
Other Unusual Items	-	-	-	-	-2.01	-
Pretax Income	-6.93	-7.43	-3.15	-5.06	-3.92	-1.22
Net Income	-6.93	-7.43	-3.15	-5.06	-3.92	-1.22
Net Income to Common	-6.93	-7.43	-3.15	-5.06	-3.92	-1.22
Shares Outstanding (Basic)	50	49	45	39	25	12
Shares Outstanding (Diluted)	50	49	45	39	25	12
Shares Change (YoY)	9.50%	7.11%	15.93%	54.71%	118.86%	15.56%
EPS (Basic)	-0.14	-0.15	-0.07	-0.13	-0.16	-0.11
EPS (Diluted)	-0.14	-0.15	-0.07	-0.13	-0.16	-0.11
EBIT	-6.88	-7.4	-3.58	-5.21	-2.01	-1.67

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 8, 2026

Data Sources Report a data error